Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease

World Journal of Gastroenterology

Volumn 19, Issue 20, 2013, Pages 3124-3129

  Niu, Xiao Ping ^a   Yu, Bao Ping ^b   Wang, Yun Dong ^b   Han, Zhen ^a   Liu, Shao Fen ^a   He, Chi Yi ^a   Zhang, Guo Zheng ^a   Wu, Wan Chun ^a  

^a Yijishan Hospital   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Non erosive reflux disease; Proton pump inhibitors; Refractoriness; Risk factors

Indexed keywords

ESOMEPRAZOLE;

ADULT; ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; BODY MASS; DEPRESSION; DISTRESS SYNDROME; ENTEROPATHY; FEMALE; HELICOBACTER INFECTION; HIATUS HERNIA; HUMAN; IRRITABLE COLON; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON EROSIVE REFLUX DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SELF-RATING ANXIETY SCALE; SHORT FORM 36; SMOKING;

EID: 84878229136     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i20.3124     Document Type: Article

References (38)

1. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008; 359: 1700-1707 [PMID: 18923172 DOI: 10.1056/NEJMcp0804684]
2. He J, Ma X, Zhao Y, Wang R, Yan X, Yan H, Yin P, Kang X, Fang J, Hao Y, Li Q, Dent J, Sung JJ, Zou D, Wallander MA, Johansson S, Liu W, Li Z. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China. BMC Gastroenterol 2010; 10: 94 [PMID: 20707933]
3. Ma XQ, Cao Y, Wang R, Yan X, Zhao Y, Zou D, Wallander MA, Johansson S, Liu W, Gu Z, Zhao J, He J. Prevalence of, and factors associated with, gastroesophageal reflux disease: a population-based study in Shanghai, China. Dis Esophagus 2009; 22: 317-322 [PMID: 19207545 DOI: 10.1111/ j.1442-2050.2008.00904.x]
4. Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 743-757 [PMID: 11003807 DOI: 10.1053/ bega.2000.0122]
5. Armstrong D. A critical assessment of the current status of non-erosive reflux disease. Digestion 2008; 78 Suppl 1: 46-54 [PMID: 18832840 DOI: 10.1159/000151255]
6. Peura DA, Berardi RR, Gonzalez J, Brunetti L. The value of branded proton pump inhibitors: formulary considerations. P T 2011; 36: 434-445 [PMID: 21931475]
7. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22: 79-94 [PMID: 16011666 DOI: 10.1111/j.1365-2036.2005.02531.x]
8. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-737 [PMID: 20662774 DOI: 10.1111/ j.1365-2036.2010.04406.x]
9. Roorda AK, Marcus SN, Triadafilopoulos G. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy. Dig Dis Sci 2011; 56: 2871-2878 [PMID: 21512760 DOI: 10.1007/s10620-011-1708-9]
10. Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T. Characteristics of nonerosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011; 17: 1858-1865 [PMID: 21528060]
11. Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Arakawa T. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol 2005; 100: 754-758 [PMID: 15784015 DOI: 10.1111/j.1572-0241.2005.40966.x]
12. Wu JC. Gastroesophageal reflux disease: an Asian perspective. J Gastroenterol Hepatol 2008; 23: 1785-1793 [PMID: 19120871 DOI: 10.1111/j.1440-1746.2008.05684.x]
13. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41: 131-137 [PMID: 17245209 DOI: 10.1097/01.mcg.0000225631.07039.6d]
14. Lee ES, Kim N, Lee SH, Park YS, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther 2009; 30: 154-164 [PMID: 19392871 DOI: 10.1111/ j.1365-2036.2009.04021.x]
15. Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of nonerosive reflux disease in Asia. World J Gastroenterol 2008; 14: 3123-3128 [PMID: 18506915]
16. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24: 747-57, e350 [PMID: 22309489 DOI: 10.1111/j.1365-2982.2012.01888.x]
17. Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil 2012; 24: 697-704 [PMID: 22783985 DOI: 10.1111/j.1365-2982.2012.01977.x]
18. Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L, Vigneri S, Camerini G, Tutuian R, Savarino V. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58: 1185-1191 [PMID: 19460766]
19. Peng S, Xiong LS, Xiao YL, Wang AJ, Lin JK, Hu PJ, Chen MH. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease. Chin Med J (Engl) 2010; 123: 2012-2017 [PMID: 20819534]
20. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-1530 [PMID: 17661525 DOI: 10.2165/00003495-200767110-00001]
21. Savarino E, Zentilin P, Savarino V. The reason for failure of on-demand PPI therapy in NERD patients. Neurogastroenterol Motil 2011; 23: 811 [PMID: 21762283 DOI: 10.1111/ j.1365-2982.2011.01722.x]
22. Wong WM, Lam KF, Lai KC, Hui WM, Hu WH, Lam CL, Wong NY, Xia HH, Huang JQ, Chan AO, Lam SK, Wong BC. A validated symptoms questionnaire (Chinese GERDQ) for the diagnosis of gastro-oesophageal reflux disease in the Chinese population. Aliment Pharmacol Ther 2003; 17: 1407-1413 [PMID: 12786635 DOI: 10.1046/j.1365-2036.2003.01576.x]
23. Savarino V, Savarino E, Parodi A, Dulbecco P. Functional heartburn and non-erosive reflux disease. Dig Dis 2007; 25: 172-174 [PMID: 17827934 DOI: 10.1159/000103879]
24. Savarino E, Marabotto E, Zentilin P, Frazzoni M, Sammito G, Bonfanti D, Sconfienza L, Assandri L, Gemignani L, Malesci A, Savarino V. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis 2011; 43: 542-547 [PMID: 21376679 DOI: 10.1016/j.dld.2011.01.016]
25. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96: 1998-2004 [PMID: 11467624 DOI: 10.1111/j.1572-0241.2001.03932.x]
26. Li Y, Nie Y, Sha W, Su H. The link between psychosocial factors and functional dyspepsia: an epidemiological study. Chin Med J (Engl) 2002; 115: 1082-1084 [PMID: 12173597]
27. Ware JE, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M. The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1159-1165 [PMID: 9817133 DOI: 10.1016/ S0895-4356(98)00107-3]
28. Savarino E, Zentilin P, Tutuian R, Pohl D, Casa DD, Frazzoni M, Cestari R, Savarino V. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103: 2685-2693 [PMID: 18775017 DOI: 10.1111/ j.1572-0241.2008.02119.x]
29. Savarino E, Tutuian R, Zentilin P, Dulbecco P, Pohl D, Marabotto E, Parodi A, Sammito G, Gemignani L, Bodini G, Savarino V. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol 2010; 105: 1053-1061 [PMID: 19997095 DOI: 10.1038/ajg.2009.670]
30. Cheung TK, Wong BC, Lam SK. Gastro-oesophageal reflux disease in Asia: birth of a 'new' disease? Drugs 2008; 68: 399-406 [PMID: 18318559 DOI: 10.2165/00003495-200868040-00001]
31. Heading RC, Mönnikes H, Tholen A, Schmitt H. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011; 11: 52 [PMID: 21569313]
32. Long JD, Orlando RC. Nonerosive reflux disease. Minerva Gastroenterol Dietol 2007; 53: 127-141 [PMID: 17557041]
33. van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME. Maintenance treatment for GERD: residual symptoms are associated with psychological distress. Digestion 2008; 77: 207-213 [PMID: 18617743 DOI: 10.1159/000143796]
34. Kim N, Lee SW, Cho SI, Park CG, Yang CH, Kim HS, Rew JS, Moon JS, Kim S, Park SH, Jung HC, Chung IS. The prevalence of and risk factors for erosive oesophagitis and nonerosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther 2008; 27: 173-185 [PMID: 17973646]
35. Oh JH, Kim TS, Choi MG, Lee H, Jeon EJ, Choi SW, Lee C, Chung IS. Relationship between Psychological Factors and Quality of Life in Subtypes of Gastroesophageal Reflux Disease. Gut Liver 2009; 3: 259-265 [PMID: 20431758 DOI: 10.5009/gnl.2009.3.4.259]
36. Kovács Z, Kerékgyártó O. Psychological factors, quality of life, and gastrointestinal symptoms in patients with erosive and non-erosive reflux disorder. Int J Psychiatry Med 2007; 37: 139-150 [PMID: 17953232 DOI: 10.2190/1147-44K4-MMQQ-122X]
37. Hartono JL, Mahadeva S, Goh KL. Anxiety and depression in various functional gastrointestinal disorders: do differences exist? J Dig Dis 2012; 13: 252-257 [PMID: 22500787 DOI: 10.1111/j.1751-2980.2012.00581.x]
38. Zerbib F, Belhocine K, Simon M, Capdepont M, Mion F, Bruley des Varannes S, Galmiche JP. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012; 61: 501-506 [PMID: 21997546 DOI: 10.1136/ gutjnl-2011-300798]